Cancers | Free Full-Text | Targeting KRAS in Cancer: Promising Therapeutic Strategies
![PDF] KRasG12C inhibitors in clinical trials: a short historical perspective† †Electronic supplementary information (ESI) available. See DOI: 10.1039/d0md00096e | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/79175af828886f5f656cc808296d9057e16dceaa/2-Figure1-1.png "PDF] KRasG12C inhibitors in clinical trials: a short historical perspective† †Electronic supplementary information (ESI) available. See DOI: 10.1039/d0md00096e | Semantic Scholar")
PDF] KRasG12C inhibitors in clinical trials: a short historical perspective† †Electronic supplementary information (ESI) available. See DOI: 10.1039/d0md00096e | Semantic Scholar
Ongoing clinical trials involving direct targeting of KRAS. | Download Scientific Diagram
World Lung 2019 – Amgen tries to keep the pace in Kras chase | Evaluate
Enhanced binding of AMG 510 to KRAS(G12C) results in improved... | Download Scientific Diagram
Asco 2019 – KRAS chase heats up with Amgen data | Evaluate
The Discovery Of Amgen's Novel Investigational KRAS(G12C) Inhibitor AMG 510 Published In Nature
Discovery of a Covalent Inhibitor of KRASG12C (AMG 510) for the Treatment of Solid Tumors | Journal of Medicinal Chemistry
Sotorasib: a KRASG12C inhibitor for non-small cell lung cancer: Trends in Pharmacological Sciences
SHP2 and SOS1 Targets: Additional Players in the KRAS Inhibitors Race?
Mixed data: AMG 510 in tumours with KRASG12C - Medical Conferences
Amgen's AMG 510 Targeted Cancer Therapy (NASDAQ:AMGN) | Seeking Alpha
Amgen unveils its KRas inhibitor in human clinical trials
KRAS Inhibitor Shows Promise in Early Trial - NCI
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity | Nature
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity | Nature
Understanding the influence of AMG 510 on the structure of KRASG12C empowered by molecular dynamics simulation - ScienceDirect
The Discovery Of Amgen's Novel Investigational KRASG12C Inhibitor AMG 510
CodeBreak 100: results show durability of clinical benefit with sotorasib in patients with non-small cell lung cancer - Onco Americas
Frontiers | Targeting KRAS Mutant in Non-Small Cell Lung Cancer: Novel Insights Into Therapeutic Strategies
Amgen unveils its KRas inhibitor in human clinical trials
KRAS(G12C)–AMG 510 interaction dynamics revealed by all-atom molecular dynamics simulations | Scientific Reports
KRAS(G12C)–AMG 510 interaction dynamics revealed by all-atom molecular dynamics simulations | Scientific Reports
Anti-Tumor Drug AMG 510 Shows Promise in Phase 1 Trial | City of Hope
RSC Medicinal Chemistry
Cancer Drug Discovered with ALS Help Enters Phase 2 Trials - Biosciences Area
Frontiers | The Renaissance of KRAS Targeting in Advanced Non-Small-Cell Lung Cancer: New Opportunities Following Old Failures
